![\"\"](\"https:\/\/ahrp.org\/wp-content\/uploads\/2019\/01\/Meryl-Nass-MD-2.jpg\")
<\/a><\/p>\nMeryl Nass, MD<\/p>\n<\/div>\n
Dr. Meryl Nass has uncovered a hornet\u2019s nest of government sponsored Hydroxychloroquine experiments that were designed to kill severely ill, Covid-19 hospitalized patients. On June 14th<\/sup>\u00a0Dr. Nass first identified two Covid-19 experiments in which massive, high toxic doses \u2013 four times higher than safe of hydroxychloroquine were being given to severely ill hospitalized patients in intensive care units.<\/p>\n Update:\u00a0<\/strong>After Dr. Nass\u2019 discovery was publicly disseminated, the WHO suspended the trial on Wednesday June 17th<\/sup>.<\/p>\n On Friday, June 19th<\/sup>, Dr. Nass uncovered a third, \u201cEven Worse\u201d hydroxychloroquine experiment. REMAP targets patients who are on a ventilator, or in shock \u2013 i.e., near death. Such patients are hardly capable of giving consent. Rather than attempting to save their lives, they are being used given multiple high doses of hydroxychloroquine and other drugs whose combination is contraindicated.<\/p>\n Of note: All the online protocols have been stamped \u201cNot for IRB (Institutional Review Board) submission<\/strong>,\u201d<\/p>\n This is an ongoing medical atrocity being perpetrated by medical doctors at\u00a0200 sites in 14 countries<\/a>: include: Australia, Belgium, Canada, Croatia, Germany, Hungary, Ireland, Netherlands, New Zealand, Portugal, Romania, Spain, United Kingdom, and the United States of America.<\/p>\n Paracelsus<\/p>\n<\/div>\n Since all medicines are potential poison at high doses, why one wonders, are influential academic physicians and international public health institutions designing and conducting experiments that expose extremely vulnerable patients to poisonous levels of the drug Hydroxychloroquin?<\/p>\n As recognized by the Swiss physician Paracelsus, \u201cthe Hippocrates of the Renaissance\u201d: Dr. Meryl Nass is a physician practicing individualized medicine in Maine, in accordance with the Hippocratic Oath. She is a longtime member of the board of the Alliance for Human Research Protection<\/p>\n *******************<\/p>\n Friday, June 19, 2020 What could be worse than giving\u00a0potentially lethal doses of hydroxychloroquine<\/a>\u00a0to Hospitalized Covid-19 patients?<\/p>\n The REMAP-Covid study is using the same HCQ dose as the\u00a0Recovery trial<\/a>\u00a0for 6 days.\u00a0 But it is even worse for the following reasons:<\/p>\n From the\u00a0Covid protocol<\/a>\u00a0page 23:<\/p>\n \u201cDosing will be hydroxychloroquine administered by the enteral route. A loading dose is important because of the large volume of distribution. The loading dose will be 800 mg, administered 6-hourly, until 2 doses have been administered. Subsequently, starting 12 hours after the first loading dose, the dose will be 400 mg administered 12-hourly for 12 doses. The preferred method of administration is tablets swallowed whole but, if a patient is unable to swallow, crushed tablets dispersed in water can be administered via an enteral tube (a large bore gastric tube is preferred). No dose adjustment is required when hydroxychloroquine is administered via a gastric tube. No dose adjustment is necessary for renal dysfunction or concomitant use of renal replacement therapy. Clinicians should consider a dose adjustment in the presence of liver failure, however no dose adjustment is necessary for abnormal liver function tests in the absence of liver failure.<\/em><\/p>\n This is 2400 mg hydroxychloroquine in the first 24 hrs, over 1.86 g of the \u201cbase,\u201d then 800 mg\/day for 5 more days or until discharge from the ICU, or 6.4 g total. Dosing fails to take into account weight, renal and hepatic function.<\/p>\n The ignorant doctors who justified toxic doses by invoking \u2018volume of distribution\u2019 (which is 40,000 liters) failed to notice that the high \u2018volume of distribution\u2019 is an\u00a0artifact related to the drug accumulating in tissue<\/a>\u00a0as opposed to plasma.\u00a0 Drug levels in lung are 200-700 times higher than in plasma.\u00a0Furthermore, \u201crenal and hepatic insufficiency lead to higher plasma concentrations for a given daily dose and raise the risk of toxicity.<\/a>\u201d<\/p>\n WHO\u2019s consultant Weniger\u00a0reported<\/a>\u00a0in 1979 that a single dose of 1.5-2 g of chloroquine \u201cbase\u201d\u00a0\u201cmay be fatal.\u201d<\/em>\u00a0A detailed discussion of therapeutic and toxic doses of chloroquine and hydroxychloroquine can be found in my\u00a0article<\/a>\u00a0of June 14. I acknowledge that hydroxychloroquine is a bit less toxic than chloroquine.\u00a0 But this trial studies the most fragile human beings, and if the trial investigators were unsure of the right dose, they should have \u201cstarted low and gone slow<\/a>\u201d as clinicians are advised to do.<\/p>\n The REMAP study protocol acknowledges that the combination of lopinavir\/ritonavir and hydroxychloroquine increases the risk of ventricular arrhythmia, but states that the risk is mitigated because patients this sick will be on cardiac monitors, with QTc monitoring.\u00a0 However, it fails to say that the most likely arrhythmia in this setting is\u00a0torsade de points,\u00a0<\/em>which is very difficult to treat.\u00a0 Patients who are already critically ill are unlikely to survive if it occurs.\u00a0 So why use such an excessive hydroxychloroquine dose on these, or any, patients, and risk it?\u00a0 That is not explained.<\/p>\n The REMAP clinical trial is ongoing in\u00a0200 sites in 14 countries<\/a>. They include:\u00a0Australia, \u00a0 Belgium, \u00a0 Canada, \u00a0 Croatia, \u00a0 Germany, \u00a0 Hungary, \u00a0 Ireland, \u00a0 Netherlands, \u00a0 New Zealand, \u00a0 Portugal, \u00a0 Romania, \u00a0 Spain, \u00a0 United Kingdom, USA.<\/p>\n All their online protocols have been stamped \u201cNot for IRB (Institutional Review Board) submission,\u201d which makes one wonder what was changed when the trial arms were put before IRBs for approval.<\/p>\n Five UK chief medical officers wrote a \u201cDear Colleague\u201d\u00a0letter<\/a>, begging physicians to enroll their Covid patients in clinical trials, including \u2018Recovery\u2019 and REMAP, and discouraging \u201coff-label\u201d treatments for Covid outside of trials.\u00a0 Did they know they were asking treating physicians to significantly up the risk of death for their patients?\u00a0 Are they aware that as of today, June 19, the\u00a0UK has had more deaths<\/a>\u00a0from Covid-19 than any country in the world outside the US and Brazil, with 5 and 3 times the UK population, respectively.<\/p>\n Why is public health being turned on its head?\u00a0 This is the third major, multicenter clinical trial of hydroxychloroquine testing toxic doses on Covid patients.\u00a0 The\u00a0Recovery<\/a>\u00a0and\u00a0Solidarity<\/a>\u00a0trials (with almost identical toxic HCQ doses as REMAP) abruptly ended their hydroxychloroquine studies in the past two weeks, coincidentally as people began noticing the excessive doses, especially on Twitter.\u00a0 Who or what is willing to maim and kill patients in order to to kill hydroxychloroquine\u2019s use in Covid-19?<\/p>\n \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ********<\/strong><\/p>\n \u00a0<\/strong>WHO and UK trials using potentially lethal hydroxychloroquine dose\u2013according to WHO consultant,<\/strong> The\u00a0Solidarity Trial\u00a0<\/a>is a WHO-led conglomeration of\u00a0many national trials of treatments for Covid-19.<\/a>\u00a0Per the\u00a0WHO<\/a>:<\/p>\n As of 3 June 2020, more than 3500 patients have been recruited in 35 countries, with over 400 hospitals actively recruiting patients.\u00a0Overall, over 100 countries have joined or expressed an interest in joining the trial, and WHO is actively supporting 60 of them\u2026<\/em><\/p>\n The\u00a0hydroxychloroquine arm of the Solidarity trials restarted enrolling patients June 3, after being halted\u00a0 May 25<\/a>\u00a0by WHO Director-General Dr. Tedros Ghebreyesus and the Executive Group of the Solidarity Trial. (The hydroxychloroquine (HCQ) arm of the trials was stopped after publication of the Lancet Surgisphere study, which claimed 35% higher death rates in patients who received hydroxychloroquine, but the\u00a0study was retracted<\/a>\u00a0when no one could verify that the Surgisphere database existed).<\/p>\n Below are the\u00a0drugs being tested in Solidarity<\/a>:<\/p>\n However, the doses were not specified on WHO\u2019s list of the drugs to be trialed, nor were the actual doses specified, surprisingly, in\u00a0WHO\u2019s consultation on chloroquine (CQ) dosing<\/a>, dated April 8. Instead, the introduction of the report of that meeting notes,<\/p>\n \u201cThe chloroquine or hydroxychloroquine schedule selected for the trial includes two oral loading doses (250 mg per tablet CQ or 200 mg per tablet HCQ), then oral twice-daily maintenance doses for ten days. This meeting convened to discuss the appropriateness of the selected doses for the trial.\u201d<\/em><\/p>\n Last week, I was alerted to the fact that India\u2019s ICMR, its official medical research agency, had\u00a0written<\/a>\u00a0to the WHO, telling WHO that the hydroxychloroquine doses being used in the Solidarity trial were\u00a04 times higher\u00a0than the doses being used in India.\u00a0 Then I learned that Singapore has been hesitant to participate in the WHO trial, due to the hydroxychloroquine dose.<\/p>\n The UK \u201cRecovery\u201d trial was one part of the international Solidarity conglomeration of clinical trials.\u00a0\u00a0The trial ended its HCQ arm on June 4,\u00a0reporting no benefit<\/a>. In-hospital mortality of the 1542 patients receiving hydroxychloroquine was 25.7%, or 396 people.<\/p>\n The Recovery trial\u00a0Study Protocol<\/a>\u00a0notes it is\u00a0funded in part by the Wellcome Trust and the Bill and Melinda Gates Foundation, and by UK government agencies.\u00a0 The\u00a0Protocol\u00a0<\/a>provides the doses of hydroxychloroquine used, on page 22.\u00a0\u00a0Twitter users began to notice a dosing issue, with hashtag #Recoverygate.<\/p>\n The quote from the WHO report on dosing, 4 paragraphs ago, seems to be deliberately vague or even misleading, as the actual dose used in the Solidarity and Recovery trials is 12 tablets during the first 24 hours (800mg initial dose, 800 mg six hours later, 400 mg 6 hrs later, 400 mg 6 hours later), then 400 mg every 12 hours\u00a0for 9 more days.\u00a0 This is 2,400 mg during the first 24 hours, and a cumulative dose of 9.2 grams over 10 days.<\/p>\n While I could not find the WHO HCQ dosing on the WHO website, co-Principal Investigators of the Recovery trial, Drs. Peter Horby and Martin Landray, claimed they followed the WHO dosing.\u00a0 Landray also told the periodical\u00a0Paris Soir<\/em>\u00a0he was using the same hydroxychloroquine dose used for amebiasis.\u00a0 However, the accepted use for HCQ in amebiasis is\u00a0only for a liver abscess and only then in pregnancy<\/a>, when other drugs cannot be used.\u00a0 That dose is 600 mg per day for 2 days, then 300 mg per day, less than half the Recovery dose.\u00a0 Professor Horby said that\u00a0Paris Soir<\/em>\u00a0misinterpreted Landray\u2019s comments, but\u00a0Paris Soir<\/em>\u00a0said Landray had confirmed<\/a>\u00a0what he told them in an email.<\/p>\n We also know, from an\u00a0official Belgian guideline document issued June 8<\/a>, that high doses were used not only by Recovery in the UK, but also by the Discovery trial in the EU and by the WHO.<\/p>\n We also know that in Brazil, both a high dose and a low dose were trialed, and\u00a0by April 17<\/a>\u00a0the\u00a0high dose arm was stopped prematurely<\/a>\u00a0due to an excess of deaths.\u00a0 The low dose trial continues in Brazil.<\/p>\n How is the drug hydroxychloroquine normally used?\u00a0 For chronic daily use in systemic lupus erythematosus or rheumatoid arthritis, patients usually receive between 200 and 400 mg daily.\u00a0 In acute Q fever, 600 mg daily may be given at the start of treatment.<\/p>\n We also know from WHO\u2019s March 13\u00a0Informal\u00a0consultation on the potential role of chloroquine<\/a>\u00a0that the Gates Foundation had been studying the drug\u2019s pharmacokinetics, and of the 25 participants at this\u00a0meeting<\/a>, 5 were from the Gates Foundation.<\/p>\n The only treatment dose mentioned in their\u00a0report<\/a>\u00a0was in a paragraph about preventive doses.\u00a0 It said,\u00a0\u201cHigher doses would be considered for treatment, i.e., 10mg\/kg base, followed by 5mg\/kg twice daily for seven days.\u201d\u00a0<\/em><\/p>\n What is the \u201cbase\u201d?\u00a0 A 200 mg dose of chloroquine or\u00a0hydroxychloroquine contains 155 mg \u201cbase\u201d<\/a>\u00a0drug.<\/p>\n The typical 70 kg person would, if this suggestion had been followed, receive 700 mg base, or\u00a0 900 mg of hydroxychloroquine, as a loading dose.\u00a0Generally, a loading dose refers only to a first dose, not to several additional doses within 24 hours, but it can potentially refer to more.<\/p>\n What is a toxic dose?\u00a0 All experts agree. \u201c\u2026 chloroquine has a small toxic to therapeutic margin,<\/em>\u201d according to\u00a0Goldfrank\u2019s Toxicologic Emergencies<\/u>.\u00a0 It is very safe when used correctly in the right patients, but a bit more can potentially kill.\u00a0 Prof. Nicholas White, who attended both WHO consultations on the chloroquines, has mentioned this.<\/p>\n The WHO hired a consultant to explore the toxicity of hydroxychloroquine in 1979.\u00a0The consultant, H. Weniger, looked at 335 episodes of adult poisoning by chloroquine drugs.\u00a0 Weniger on\u00a0page 5 notes that a single dose of 1.5-2 grams of hydroxychloroquine base \u201cmay be fatal.<\/a>\u201d<\/p>\n The Recovery trial used 1.860 grams hydroxychloroquine base (equal to 2400 mg of hydroxychloroquine) in the first 24 hours for treatment of already very ill, hospitalized Covid-19 patients, a potentially lethal dose.<\/p>\n The dose used in the Recovery trial is not recommended for therapy of any medical condition, which I confirmed with Goodman and Gilman\u2019s Pharmacology textbook, the drug\u2019s\u00a0label<\/a>, and the online medical encyclopedia UptoDate.<\/p>\n This excessive dose apparently continues to be used in WHO Solidarity trials in countries around the world. It appears that the Solidarity trials are not testing the benefits of HCQ on Covid-19, but rather testing whether patients tolerate toxic, nontherapeutic doses.<\/p>\n The WHO Solidarity trials, in order to rapidly enroll patients and spare clinicians a lot of paperwork, collect only limited information on side effects.\u00a0 No information has yet been provided regarding causes of death in the completed hydroxychloroquine arm of the Recovery trial, in which 396 patients died.<\/p>\n The Solidarity trial design being employed by WHO may help obscure whether mortality is due to drug toxicity (in which case, one would expect cause of death to be arrhythmias such as torsade de points, neuropsychiatric effects, or hypoglycemia) versus Covid-19.<\/p>\n\n
<\/a><\/p>\n
\n\u201cWhat is there that is not poison? All things are poison and nothing is without\u00a0<\/a>poison. Solely the dose determines that a thing is not a poison.<\/em>\u201d\u00a0His insight is as relevant today as it was in the 16th century.<\/p>\n
\n<\/strong>Even worse than \u2018Recovery,\u2019 potentially lethal hydroxychloroquine study in patients near death<\/a><\/strong><\/p>\n\n
\nposted June 14, 2020<\/p>\n\n